Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease (AEGIS-CKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02968368
Recruitment Status : Completed
First Posted : November 18, 2016
Results First Posted : May 1, 2020
Last Update Posted : May 14, 2020
Sponsor:
Information provided by (Responsible Party):
Shield Therapeutics

Brief Summary:
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD

Condition or disease Intervention/treatment Phase
Renal Insufficiency, Chronic Iron-Deficiency Anemia Drug: Ferric maltol Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 167 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
Actual Study Start Date : December 1, 2016
Actual Primary Completion Date : January 18, 2018
Actual Study Completion Date : October 10, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oral ferric maltol
30mg capsules BID
Drug: Ferric maltol
Other Name: Feraccru

Placebo Comparator: Oral placebo
Matching placebo capsules BID
Other: Placebo



Primary Outcome Measures :
  1. Change in Hb Concentration From Baseline to Week 16 [ Time Frame: 16 weeks ]
    Change in hemoglobin concentration from baseline to Week 16.


Secondary Outcome Measures :
  1. Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16 [ Time Frame: 16 weeks ]
    Number of subjects that achieve an increase in Hemoglobin concentration of ≥1 g/dL at Week 16

  2. Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16 [ Time Frame: 16 weeks ]
    Number of subjects that achieve a Hemoglobin concentration of ≥11 g/dL at week 16

  3. Change in Hb Concentration From Baseline to Week 8 [ Time Frame: 8 weeks ]
    Change in Hemoglobin concentration from baseline to Week 8

  4. Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16 [ Time Frame: 16 weeks ]
    Number of subjects that achieve an increase in Hemoglobin concentration of ≥2 g/dL at Week 16

  5. Changes in Ferritin From Baseline to Week 16 [ Time Frame: baseline to week 16 ]
    Changes in iron parameter - ferritin - from baseline to week 16

  6. Number of Participants With (TEAEs) [ Time Frame: Week 16 ]
    Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

  7. Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) [ Time Frame: Week 16 ]
    Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the double blind phase

  8. Changes in TSAT From Baseline to Week 16 [ Time Frame: baseline to week 16 ]
    Changes in iron parameters - TSAT - from baseline to week 16

  9. Changes in Iron Parameter From Baseline to Week 16 [ Time Frame: from baseline to week 16 ]
    Changes in iron parameters - serum iron - from baseline to week 16

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Week 52 ]
    Number of Participants with Treatment-Emergent Adverse Events (TEAEs) during the open label phase

  11. Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) [ Time Frame: Week 52 ]
    Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the open label phase



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved information sheet and consent form. Must sign and date the informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations prior to any study mandated procedure.
  2. Willing and able to comply with study requirements.
  3. Age ≥ 18 years at the time of informed consent.
  4. A current diagnosis of CKD with an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 and ≥15 mL/min/1.73m2, as calculated using the abbreviated version of the Modified Diet in Renal Disease equation (MDRD) assessed via screening laboratory results.
  5. Iron deficiency anemia defined by the following criteria assessed via screening laboratory results:

    1. Hb <11.0g/dL and ≥8.0g/dL
    2. AND ferritin <250ng/mL with a Transferrin saturation (TSAT) <25% OR ferritin <500ng/mL with a TSAT of <15%
  6. Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, a vasectomized partner and oral contraceptive medications. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to participate.

Exclusion Criteria:

  1. Anemia due to any cause other than iron deficiency, including, but not limited to:

    1. Untreated or untreatable severe malabsorption syndrome.
    2. Myelosuppression use (permitted if taken at a stable dose and frequency for at least 12 weeks prior to randomization and are expected to stay stable throughout the double-blind treatment period so long as there is no clinical evidence of the myelosuppression contributing to the subject's anemia).
  2. Administration with any of the following prior to randomization:

    1. IV iron injection within the previous 4 weeks or administration of intramuscular or depot iron preparation within the previous 12 weeks.
    2. Single agent oral iron supplementation, taken specifically to treat anemia (e.g. ferrous sulfate, fumarate and gluconate) within the previous 2 weeks. Multivitamins are permitted.
    3. Use if ferric citrate and sucroferric oxyhydroxide within the previous 1 week.
    4. ESAs within the previous 4 weeks
    5. Blood transfusion or donation within the previous 12 weeks.
    6. Dimercaprol or cloramphenicol within the previous 7 days.
    7. Current use of methyldopa.
  3. Currently receiving dialysis or initiation of dialysis is considered likely during the study.
  4. Renal transplant within 12 months prior to randomization or is considered likely during the study.
  5. Known hypersensitivity or allergy to the active substance or excipients of ferric maltol or placebo capsules.
  6. Contraindication for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anemia, thalassemia, or lead intoxication induced anemia.
  7. Impaired liver function as indicated by alanine aminotransferase (ALT) or aspartate transaminase (AST) > 3 times the upper limit of normal as assessed via screening laboratory results.
  8. Clinically significant vitamin B12 or folic acid deficiency as determined by the screening laboratory results (retest following at least 2 weeks of starting treatment with vitamin B12 or folate replacement is permitted).
  9. Pregnant or breast feeding.
  10. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anemia; for example coagulation disorders or recurrent GI bleeding.
  11. Scheduled or expected major surgery during the course of the study. (Minor surgeries not associated with significant blood loss, in the Investigator's judgement, are permitted e.g. surgery related to fistulae or vascular access, minor dental extractions, incision and drainage of abscess or simple excisions).
  12. Participation in any other interventional clinical study within 30 days prior to screening.
  13. Cardiovascular, liver, renal, hematologic, psychiatric, neurologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject.
  14. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor make the subject unsuitable for enrolment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02968368


Locations
Layout table for location information
United States, Arizona
Peoria, Arizona, United States
Phoenix, Arizona, United States
Prescott, Arizona, United States
Tucson, Arizona, United States
United States, California
La Mesa, California, United States
Long Beach, California, United States
Roseville, California, United States
Sacramento, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Florida
Coral Springs, Florida, United States
Edgewater, Florida, United States
Lauderdale Lakes, Florida, United States
Miami, Florida, United States
United States, Georgia
Macon, Georgia, United States
United States, Louisiana
Shreveport, Louisiana, United States
United States, Michigan
Pontiac, Michigan, United States
Roseville, Michigan, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, North Carolina
Asheville, North Carolina, United States
Charlotte, North Carolina, United States
Wilmington, North Carolina, United States
United States, Pennsylvania
Bethlehem, Pennsylvania, United States
United States, Tennessee
Knoxville, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
El Paso, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Hampton, Virginia, United States
Sponsors and Collaborators
Shield Therapeutics
Investigators
Layout table for investigator information
Study Director: Mark Sampson, MBChB Shield Therapeutics
  Study Documents (Full-Text)

Documents provided by Shield Therapeutics:
Layout table for additonal information
Responsible Party: Shield Therapeutics
ClinicalTrials.gov Identifier: NCT02968368    
Other Study ID Numbers: ST10-01-303
First Posted: November 18, 2016    Key Record Dates
Results First Posted: May 1, 2020
Last Update Posted: May 14, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ferric maltol
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Anemia
Anemia, Iron-Deficiency
Deficiency Diseases
Hematologic Diseases
Urologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Malnutrition
Nutrition Disorders
Hematinics